{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:23:22Z","timestamp":1782476602437,"version":"3.54.5"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.7759\/cureus.110075","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:16Z","timestamp":1780358416000},"source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab Dual Endocrine Toxicity in a Metastatic Non-small Cell Lung Cancer Patient"],"prefix":"10.7759","author":[{"given":"Sawsan","family":"Al-Lababidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rand","family":"Alkhlaifat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Herrera-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshi","family":"Sunderam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye ES","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al.. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022, 187:G1-21. 10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan L","year":"2021","unstructured":"Zhan L, Feng HF, Liu HQ, Guo LT, Chen C, Yao XL, Sun SR. Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management. Front Endocrinol (Lausanne). 2021, 12:649863. 10.3389\/fendo.2021.649863","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae200","article-title":"Pembrolizumab-induced thyroiditis, hypophysitis and adrenalitis: a case of triple endocrine dysfunction","volume":"2","author":"Rossi S","year":"2024","unstructured":"Rossi S, Silvetti F, Bordoni M, Ciarloni A, Salvio G, Balercia G. Pembrolizumab-induced thyroiditis, hypophysitis and adrenalitis: a case of triple endocrine dysfunction. JCEM Case Rep. 2024, 2:luae200. 10.1210\/jcemcr\/luae200","journal-title":"JCEM Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15465","article-title":"Pembrolizumab-induced hypophysitis with isolated adrenocorticotropic hormone (ACTH) deficiency: a rare immune-mediated adverse event","volume":"13","author":"Doodnauth AV","year":"2021","unstructured":"Doodnauth AV, Klar M, Mulatu YS, Malik ZR, Patel KH, McFarlane SI. Pembrolizumab-induced hypophysitis with isolated adrenocorticotropic hormone (ACTH) deficiency: a rare immune-mediated adverse event. Cureus. 2021, 13:e15465. 10.7759\/cureus.15465","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis DA","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, et al.. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017, 102:2770-80. 10.1210\/jc.2017-00448","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi G","year":"2019","unstructured":"Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Rev Endocrinol Metab. 2019, 14:381-98. 10.1080\/17446651.2019.1701434","journal-title":"Expert Rev Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/492405-pembrolizumab-dual-endocrine-toxicity-in-a-metastatic-non-small-cell-lung-cancer-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:16Z","timestamp":1780358416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/492405-pembrolizumab-dual-endocrine-toxicity-in-a-metastatic-non-small-cell-lung-cancer-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.110075","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}